Shots:

• The CHMP has granted a positive opinion to Ryzeneuta (20mg, IV) based on its safety and efficacy evaluation results as compared to PBO
• The recommendation was made by CHMP for EC’s approval as a medicinal product for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy
• Efembalenograstim alfa is an immunostimulant/colony-stimulating factor belonging to the class of haematopoietic growth factors that functions by increasing the production and differentiation of mature and functionally active neutrophils from bone marrow precursor cells

Ref: Evive Biotechnology | Image: Evive Biotechnology

Related Post:- Coherus BioSciences Reports the Pooled Analysis of Udenyca (biosimilar, pegfilgrastim) Demonstrated Similar Immunogenicity to Neulasta

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com